Literature DB >> 2272706

Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in man.

J M Brogard1, F Jehl, J F Blickle, M Dorner, J P Arnaud, H Monteil.   

Abstract

The purpose of the present experimental and clinical work is to revisit the biliary pharmacokinetic properties of piperacillin. Whereas the up to now published data result from microbiological assays, this work was realized by high performance liquid chromatography. In the isolated and perfused rabbit liver model (n = 5; 3 h), the biliary level peaked at 1,013 +/- 305 micrograms/ml between 30 and 60 min. During the experiments, 56.7% and 10.8% of the administered piperacillin (10 mg) were respectively eliminated in bile and submitted to hepatic biotransformation. In man, a single 2 g i.v. dose was administered to 6 volunteers. The excretion measured in the duodenal fluid was 1,681 +/- 601 micrograms in 4 h (0.08% of the administered dose). In cholecystectomized patients (n = 10) provided with a T-drain, the biliary peak concentration was 211 +/- 64 micrograms/ml during the 2nd h, and the 24 h biliary elimination was 12,963 +/- 3,332 micrograms, representing 0.65% of the administered dose. The hepato-biliary clearance was 0.80 ml/min. On per-operatively collected serum, choledocal bile, gallbladder bile and gallbladder wall samples (n = 10 patients), the concentrations of piperacillin simultaneously measured 1 h after the i.v. administration of 2 g were respectively, 81.7 +/- 20.5, 382 +/- 110, 30.8 +/- 2.5 micrograms/ml and 10.5 +/- 2.6 micrograms/g.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2272706

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  7 in total

1.  Assessment of biliary excretion of piperacillin-tazobactam in humans.

Authors:  J F Westphal; J M Brogard; F Caro-Sampara; M Adloff; J F Blicklé; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

3.  Determination of the biliary excretion of piperacillin in humans using a novel method.

Authors:  Giulia Ghibellini; Lakshmi S Vasist; Terence E Hill; William D Heizer; Richard J Kowalsky; Kim L R Brouwer
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 4.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

5.  Plasma levels of piperacillin and vancomycin used as prophylaxis in liver transplant patients.

Authors:  M Dupon; G Janvier; G Vinçon; S Winnock; F Demotes-Mainard; O Capeyron; J Saric
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles.

Authors:  Tom N Lea-Henry; Jane E Carland; Sophie L Stocker; Jacob Sevastos; Darren M Roberts
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-22       Impact factor: 8.237

7.  Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?

Authors:  Jason A Roberts; Darren M Roberts
Journal:  Crit Care       Date:  2014-06-23       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.